Sébastien Lacroix-Desmazes, INSERM UMR 872 Equipe 16, Centre de Recherche des Cordeliers, Paris, F-75006 France.
Thromb Haemost. 2010 Dec;104(6):1093-8. doi: 10.1160/TH10-05-0294. Epub 2010 Sep 30.
The immunogenicity of therapeutic factor VIII (FVIII) in patients with haemophilia A remains a critical issue in patient management. This review describes the immunological processes involved in the activation of the immune system against FVIII, with a particular focus on the role of endocytic receptors for the recognition of FVIII by antigen-presenting cells.
治疗性因子 VIII(FVIII)在血友病 A 患者中的免疫原性仍然是患者管理中的一个关键问题。本文综述描述了针对 FVIII 的免疫系统激活所涉及的免疫学过程,特别关注了内吞受体在抗原呈递细胞识别 FVIII 中的作用。